Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.

Core Viewpoint - Pfizer is re-entering the obesity-drug market after successfully countering a rival bid from Novo Nordisk for Metsera, leveraging additional financial resources and support from the Trump administration [1] Group 1 - Pfizer's acquisition strategy is focused on regaining a foothold in the obesity treatment sector [1] - The company faced competition from Novo Nordisk, indicating a competitive landscape in the obesity-drug market [1] - Support from the Trump administration may provide Pfizer with strategic advantages in this acquisition [1]